• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>International Journal of Chronic Obstructive Pulmonary Disease >The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorized by symptom status: a pooled analysis
【24h】

The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorized by symptom status: a pooled analysis

机译：沙丁胺醇/福莫特罗对按症状状态分类的COPD患者肺功能和症状的疗效：汇总分析

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: Patients with chronic obstructive pulmonary disease (COPD) experience respiratory symptoms, which impair quality of life. This pooled analysis of two Phase III studies assessed the impact of aclidinium/formoterol on patients with COPD categorized by symptom status. Methods: Data were pooled from two 24-week, randomized, placebo-controlled studies of twice-daily aclidinium/formoterol 400/12 μg in moderate-to-severe COPD (ACLIFORM [NCT01462942] and AUGMENT [NCT01437397]). These post hoc analyses evaluated the efficacy of aclidinium/formoterol versus placebo or monotherapies in patients defined as less/more symptomatic by a) Evaluating Respiratory Symptoms (E-RS?) score ≥10/1), Transition Dyspnea Index, E-RS total score, early-morning and nighttime symptom severity, early-morning limitation of activities, and exacerbation rate. Results: Data for 3,394 patients were analyzed (mean age: 63.5 years; 60.5% male). In both definitions of less and more symptomatic patients, aclidinium/formoterol improved 1-hour morning postdose FEV1 from baseline at week 24 versus placebo ( P 1 from baseline in both groups versus placebo ( P 1, dyspnea, and early-morning symptoms.
机译：背景：患有慢性阻塞性肺疾病（COPD）的患者会出现呼吸道症状，从而影响生活质量。这项对两项三期研究的汇总分析评估了按症状状态分类的阿地丁/福莫特罗对COPD患者的影响。方法：数据来自两项针对中重度COPD的每日两次阿地丁/福莫特罗400/12μg（ACLIFORM [NCT01462942]和AUGMENT [NCT01437397]）的两项为期24周的随机，安慰剂对照研究。这些事后分析通过a）评估呼吸道症状（E-RS？）得分≥10/ 1 ），过渡型呼吸困难指数，阿司匹林/福莫特罗与安慰剂或单一疗法对被定义为症状更少/更多的患者的疗效进行了评估。 E-RS总分，早晨和夜间症状的严重程度，早晨的活动限制以及病情加重。结果：分析了3,394例患者的数据（平均年龄：63.5岁; 60.5％男性）。在越来越少有症状的患者的两种定义中，与安慰剂相比，阿曲丁铵/福莫特罗在用药后第1周早晨FEV 1 较基线改善了（两组与安慰剂相比，基线均P 1 （ P 1 ，呼吸困难和早起症状。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号